Author
Listed:
- Lisiane Freitas Leal
(Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC H3A 1A2, Canada)
- Sonia Marzia Grandi
(Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC H3A 1A2, Canada)
- Vanessa Iribarrem Avena Miranda
(Programa de Pós-graduação em Saúde Coletiva—PPGSCol, Universidade do Extremo Sul Catarinense, Criciúma 88806-000, Brazil)
- Tatiane da Silva Dal Pizzol
(Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul 90610-000, Brazil)
- Robert William Platt
(Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC H3A 1A2, Canada)
- Mariângela Freitas da Silveira
(Programa de Pós-graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal de Pelotas, Pelotas 96020-220, Brazil)
- Andréa Dâmaso Bertoldi
(Programa de Pós-graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal de Pelotas, Pelotas 96020-220, Brazil)
Abstract
Hypertensive disorders of pregnancy account for approximately 22% of all maternal deaths in Latin America and the Caribbean. Pharmacotherapies play an important role in preventing and reducing the occurrence of adverse outcomes. However, the patterns of medications used for treating women with hypertensive disorders of pregnancy (HDP) living in this country is unclear. A population-based birth cohort study including 4262 women was conducted to describe the pattern of use of cardiovascular agents and acetylsalicylic acid between women with and without HDP in the 2015 Pelotas (Brazil) Birth Cohort. The prevalence of maternal and perinatal outcomes in this population was also assessed. HDP were classified according to Ministry of Health recommendations. Medications were defined using the Anatomical Therapeutic Chemical Classification System and the substance name. In this cohort, 1336 (31.3%) of women had HDP. Gestational hypertension was present in 636 (47.6%) women, 409 (30.6%) had chronic hypertension, 191 (14.3%) pre-eclampsia, and 89 (6.7%) pre-eclampsia superimposed on chronic hypertension. Approximately 70% of women with HDP reported not using any cardiovascular medications. Methyldopa in monotherapy was the most frequent treatment (16%), regardless of the type of HDP. Omega-3 was the medication most frequently reported by women without HDP. Preterm delivery, caesarean section, low birth weight, and neonatal intensive care admissions were more prevalent in women with HDP. Patterns of use of methyldopa were in-line with the Brazilian guidelines as the first-line therapy for HDP. However, the large number of women with HDP not using medications to manage HDP requires further investigation.
Suggested Citation
Lisiane Freitas Leal & Sonia Marzia Grandi & Vanessa Iribarrem Avena Miranda & Tatiane da Silva Dal Pizzol & Robert William Platt & Mariângela Freitas da Silveira & Andréa Dâmaso Bertoldi, 2020.
"Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study,"
IJERPH, MDPI, vol. 17(22), pages 1-14, November.
Handle:
RePEc:gam:jijerp:v:17:y:2020:i:22:p:8541-:d:446744
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:22:p:8541-:d:446744. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.